A detailed history of Invesco Ltd. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 163,919 shares of KYMR stock, worth $6.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
163,919
Previous 29,834 449.44%
Holding current value
$6.66 Million
Previous $890,000 771.69%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$30.16 - $52.4 $4.04 Million - $7.03 Million
134,085 Added 449.44%
163,919 $7.76 Million
Q2 2024

Aug 13, 2024

SELL
$29.85 - $39.42 $2.49 Million - $3.29 Million
-83,533 Reduced 73.68%
29,834 $890,000
Q1 2024

May 14, 2024

BUY
$22.9 - $43.57 $1.95 Million - $3.72 Million
85,278 Added 303.6%
113,367 $4.56 Million
Q4 2023

Feb 12, 2024

SELL
$10.97 - $26.84 $93,661 - $229,159
-8,538 Reduced 23.31%
28,089 $715,000
Q3 2023

Nov 13, 2023

BUY
$13.9 - $23.88 $86,138 - $147,984
6,197 Added 20.36%
36,627 $509,000
Q2 2023

Aug 11, 2023

SELL
$22.4 - $34.92 $3.56 Million - $5.55 Million
-159,056 Reduced 83.94%
30,430 $699,000
Q1 2023

May 12, 2023

BUY
$24.84 - $38.75 $4.37 Million - $6.82 Million
175,993 Added 1304.33%
189,486 $5.61 Million
Q4 2022

Feb 13, 2023

SELL
$19.57 - $30.92 $58 - $92
-3 Reduced 0.02%
13,493 $336,000
Q3 2022

Nov 14, 2022

SELL
$20.91 - $34.27 $1,400 - $2,296
-67 Reduced 0.49%
13,496 $294,000
Q2 2022

Aug 15, 2022

SELL
$14.13 - $42.55 $25,547 - $76,930
-1,808 Reduced 11.76%
13,563 $267,000
Q1 2022

May 16, 2022

BUY
$35.3 - $64.68 $5,153 - $9,443
146 Added 0.96%
15,371 $650,000
Q4 2021

Feb 14, 2022

SELL
$49.91 - $65.56 $8,534 - $11,210
-171 Reduced 1.11%
15,225 $967,000
Q3 2021

Nov 15, 2021

BUY
$47.8 - $66.66 $293,109 - $408,759
6,132 Added 66.19%
15,396 $904,000
Q2 2021

Aug 17, 2021

BUY
$31.08 - $51.95 $287,925 - $481,264
9,264 New
9,264 $450,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.22B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.